文献速递神经肿瘤

PYK2抑制剂PF-562271增强替莫唑胺对C57Bl/6-Gl261小鼠胶质瘤模型肿瘤生长的抑制作用

The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model.
PubMed 文献 · J Neurooncol · 2023-02-15

本研究在原发性人GBM细胞培养和C57Bl/6-GL261小鼠胶质瘤植入模型中,评估Pyk2/FAK抑制剂PF-562271联合替莫唑胺(TMZ)的效果。体外实验显示TMZ(100 µM)+PF-562271(16 nM)较TMZ单药显著降低活力、细胞周期进展、侵袭和伪足形成;体内实验显示联合治疗较TMZ单药显著减小肿瘤大小和侵袭边缘、增加凋亡、降低增殖指数,并使动物生存率提高15%。结论认为TMZ+PF-562271消除TMZ相关Pyk2/FAK激活并改善疗效。

要点

  • TMZ激活GBM中FAK和Pyk2信号通路。
  • 体外TMZ(100 µM)+PF-562271(16 nM)较TMZ单药显著降低活力、细胞周期进展、侵袭和伪足形成。
  • 体内联合治疗较TMZ单药显著减小肿瘤大小和侵袭边缘、增加凋亡、降低增殖指数,动物生存率提高15%。

核心结论

  • TMZ+PF-562271消除TMZ相关Pyk2/FAK激活并改善治疗效果。

研究设计与样本

  • 使用原发性人GBM细胞培养和C57Bl/6-GL261小鼠胶质瘤植入模型。
  • 体外分析Pyk2(Tyr579/580)和FAK(Tyr925)磷酸化、活力、细胞周期、迁移、侵袭和伪足形成。
  • 体内评估TMZ(50 mg/kg,每日一次,口服)和Pyk2/FAK抑制剂PF-562271(每日一次,50 mg/kg,口服)联合治疗对比TMZ单药对动物生存、肿瘤大小和侵袭、TUNEL凋亡细胞死亡和Ki67增殖指数的影响。

主要发现

  • 体外研究显示TMZ(100 µM)+PF-562271(16 nM)较TMZ单药显著降低活力、细胞周期进展、侵袭和伪足形成。
  • 体内研究显示联合治疗较TMZ单药显著减小肿瘤大小和侵袭边缘,出现广泛凋亡迹象并降低增殖指数。
  • 联合治疗较TMZ单药使动物生存率提高15%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The development of resistance to temozolomide (TMZ), a standard chemotherapeutic, limits the effective treatment of glioblastoma (GBM). Focal adhesion kinase (FAK) and proline rich tyrosine kinase 2 (Pyk2) regulate proliferation and invasion of GBM cells. We found that TMZ activates FAK and Pyk2 signaling in GBM. We hypothesized that pharmacological inhibitors of Pyk2/FAK together with TMZ can enhance the inhibitory effect of TMZ on tumor growth and dispersal and improve the treatment outcome. METHODS: Primary human GBM cell cultures and a C57Bl/6-GL261 mouse glioma implantation model were used. Pyk2 (Tyr579/580) and FAK (Tyr925) phosphorylation was analyzed by western blotting. Viability, cell cycle, migration, invasion and invadopodia formation were investigated in vitro. Animal survival, tumor size and invasion, TUNEL apoptotic cell death and the Ki67 proliferation index were evaluated in vivo upon treatment with TMZ (50 mg/kg, once/day, orally) and the Pyk2/FAK inhibitor PF-562271 (once/daily, 50 mg/kg, orally) vs. TMZ monotherapy. RESULTS: In vitro studies revealed significantly reduced viability, cell cycle progression, invasion and invadopodia with TMZ (100 µM) + PF-562271 (16 nM) compared with TMZ alone. In vivo studies demonstrated that combinatorial treatment led to prominent reductions in tumor size and invasive margins, extensive signs of apoptosis and a reduced proliferation index, together with a 15% increase in the survival rate in animals, compared with TMZ monotherapy. CONCLUSION: TMZ + PF-562271 eliminates TMZ-related Pyk2/FAK activation in GBM and improves the treatment efficacy.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Ortiz-Rivera J, Nuñez R, Kucheryavykh Y, et al. The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model. J Neurooncol. 2023. PMID: 36790653. doi:10.1007/s11060-023-04260-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。